Percheron Therapeutics (AU:PER)
ASX:PER
Holding AU:PER?
Track your performance easily

Percheron Therapeutics (PER) Income Statement

10 Followers

Percheron Therapeutics Income Statement

Last quarter (Q4 2022), Percheron Therapeutics's total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, Percheron Therapeutics's net income was AU$―. See Percheron Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 22Jun 21Jun 20Jun 19Jun 18
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
-AU$ 7.61MAU$ 8.68MAU$ 6.67MAU$ 3.58MAU$ 2.62M
Operating Income
-AU$ -7.61MAU$ -8.68MAU$ -6.67MAU$ -3.58MAU$ -2.62M
Net Non Operating Interest Income Expense
-AU$ 22.27KAU$ -6.55KAU$ 17.99KAU$ 66.17KAU$ 25.55K
Other Income Expense
-AU$ 1.78MAU$ 629.20KAU$ 740.10KAU$ 572.47KAU$ 263.57K
Pretax Income
-AU$ -5.81MAU$ -8.06MAU$ -5.91MAU$ -2.94MAU$ -2.33M
Tax Provision
-AU$ 0.00AU$ 0.00AU$ 0.00AU$ 0.00AU$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-AU$ -5.81MAU$ -8.06MAU$ -5.91MAU$ -2.94MAU$ -2.33M
Basic EPS
-AU$ >-0.01AU$ -0.01AU$ -0.01AU$ >-0.01-
Diluted EPS
-AU$ >-0.01AU$ -0.01AU$ -0.01AU$ >-0.01-
Basic Average Shares
-AU$ 634.29MAU$ 540.98MAU$ 455.83MAU$ 386.10M-
Diluted Average Shares
-AU$ 634.29MAU$ 540.98MAU$ 455.83MAU$ 386.10M-
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
------
Net Income From Continuing And Discontinued Operation
-AU$ -5.81MAU$ -8.06MAU$ -5.91MAU$ -2.94MAU$ -2.33M
Normalized Income
-AU$ -5.81MAU$ -8.06MAU$ -5.91MAU$ -2.94MAU$ -2.33M
Interest Expense
------
EBIT
-AU$ -7.61MAU$ -8.68MAU$ -6.67MAU$ -3.58MAU$ -2.62M
EBITDA
-AU$ -7.52MAU$ -8.58MAU$ -6.56MAU$ -3.58MAU$ -2.61M
Currency in AUD

Percheron Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis